RNS Number: 2881 O Angle PLC 29 May 2020. ANGLE plc, a world-leading liquid biopsy company, announces that it will be releasing its audited preliminary results for the 8 months ended 31 December 2019 on Thursday 25 June 2020.. In accordance with COVID-19 guidance from the Financial Reporting Council and pursuant to discussions with the Company's auditors, RSM, in...
Angle 65p £112m (AGL.L) The Liquid Biopsy Analysis Unit at the Health Research Institute of Santiago, Spain has published results of new work undertaken in head and neck cancer and non small cell lung cancer on the potential utility of a liquid biopsy-based strategy to assess MET alterations on circulating tumour cells (CTCs). The researchers are the first to investigate the use of liquid biopsy systems to capture CTCs in order to investigate MET expression levels in the cancer, in a study comparing the utility of Parsortix to that of the leading antibody-based CTC system. The head and neck cancer results using Parsortix showed a significant association of the presence of MET positive CTCs, which was a minority of patients, and poorer overall survival of those patients. #AGL
Angle Plc #AGL Announced that the Liquid Biopsy Analysis Unit at the Health Research Institute of Santiago, Spain has published results of new work undertaken in head and neck cancer and non small cell lung cancer on the potential utility of a liquid biopsy-based strategy to assess MET alterations on circulating tumour cells (CTCs). MET alterations in cancer patients may provide a biomarker to evaluate which patients will benefit from treatment with a new class of drug called MET inhibitors. The MET-related cancer pathways can activate cell proliferation, survival, migration, motility, invasion, angiogenesis, apoptosis and epithelial-to-mesenchymal transition. Thus, the MET pathways have a fundamental bearing on the rate of growth and spread of cancer.
RNS Number: 5606 M Angle PLC 12 May 2020. MET EXPRESSION OF PARSORTIX-HARVESTED CTCs FROM CANCER PATIENTS HAS POTENTIAL AS BIOMARKER FOR MET INHIBITOR DRUG TRIALS. ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that the Liquid Biopsy Analysis Unit at the Health Research Institute of Santiago, Spain has published results of new work...
RNS Number: 7188 L Angle PLC 04 May 2020. LEADING CANCER CENTRE PUBLISHES PARSORTIX WORKFLOW ADDRESSING PROBLEMS WITH ALTERNATIVE APPROACHES. ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that the University of Southern California has published results of new work undertaken in advanced prostate cancer demonstrating a workflow...
RNS Number: 0435 L Angle PLC 28 April 2020. As announced on 31 March 2020, ANGLE's operations in the UK, Canada and USA have been impacted by the COVID-19 pandemic and the resulting Government directives, notably in relation to completion of the remaining analytical samples required for the Company's FDA submission and patient enrolment for the Company's...
Angle 55p £95m #AGL The liquid biopsy company, announced that the University of Athens has published results of new work undertaken in head and neck squamous cell carcinoma (HNSCC) demonstrating the use of ANGLE's Parsortix® system in the analysis of gene expression and epigenetic alterations (DNA methylation markers) on circulating tumor cells (CTCs) from a simple blood test. The results demonstrated that the Parsortix system had key advantages including: · much higher CTC harvesting positivity rates; · higher purity samples with lower levels of non-specific contaminant cells; · excellent RNA quality for molecular analysis; · higher relative expression levels for key cancer genes, including PDL1, which is a key target for immunotherapy drugs especially in this type of cancer; · significantly higher proportion of samples testing positive for epigenetic alterations in CTCs (DNA methylation markers), which is a key area for cancer investigation. *denotes a corporate client of Hybridan
ANGLE plc (AGL.L): Study published by University of Athens Share price: 53.5p; Market Capitalisation: £92.5m ANGLE plc announced that the University of Athens, Greece, published a study evaluating the analytical performance of Parsortix, the Group’s proprietary liquid biopsy in head and neck squamous cell carcinoma (HNSCC). The researchers compared the performance of Parsortix against an antibody-based circulating tumour cell (CTC) detection system and captured samples from 50 HNSCC patients and 18 healthy volunteers. The Parsortix system out-performed the alternative approach with key advantages including a higher CTC harvesting rate and purer samples. The research was published in the International Journal of Molecular Sciences (Link: Independent research, such as this study, builds clinical acceptance of the Group’s technology in different indications as it advances Parsortix through the US regulatory approval process for use in metastatic breast cancer patients. The Group met with the FDA in January as part of a Q-submission meeting and is working on completing its FDA submission. The Group remains well capitalised with cash of £15.5m at 30 March 2020 which is sufficient for planned operations until mid-2021. Liquid biopsies (blood tests) could enable early diagnosis of cancer via a simple test and is becoming a highly competitive area. CTCs represent promising biomarkers for early prediction of cancer and treatment response monitoring. #AGL
Angle Plc #AGL announced that the University of Athens has published results of new work undertaken in head and neck squamous cell carcinoma (HNSCC) demonstrating the use of ANGLE's Parsortix system in the analysis of gene expression and epigenetic alterations on circulating tumor cells (CTCs) from a simple blood test. To assess the potential for molecular characterisation of CTCs enriched by Parsortix, the researchers undertook a direct comparison of Parsortix using identical blood draws with an antibodybased approach to CTC capture for 50 HNSCC patients and 18 healthy volunteers. The results showed that Parsortix system had key advantages including much higher CTC harvesting positivity rates, higher purity samples with lower levels of non-specific contaminant cells.
RNS Number: 9483 J Angle PLC 17 April 2020. PARSORTIX PERFORMANCE DEMONSTRATED IN HEAD AND NECK CANCER. ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that the University of Athens has published results of new work undertaken in head and neck squamous cell carcinoma demonstrating the use of ANGLE's Parsortix ® system in the...
Angle Plc #AGL announced that its operations and activities in the UK, Canada and the US have all been impacted by the COVID-19 pandemic and resulting Government directives. Following the UK Prime Minister's announcement on 23 March 2020 that UK citizens should only leave their homes for certain very limited purposes, the company took the decision to temporarily cease operations at the ANGLE UK laboratories and offices.
RNS Number: 1356 I Angle PLC 31 March 2020. ANGLE's operations and activities in the UK, Canada and the US have all been impacted by the COVID-19 pandemic and resulting Government directives. Following the UK Prime Minister's announcement on 23 March 2020 that UK citizens should only leave their homes for certain very limited purposes, we took the decision to...
RNS Number: 1356 I Angle PLC 31 March 2020. ANGLE's operations and activities in the UK, Canada and the US have all been impacted by the COVID-19 pandemic and resulting Government directives. Following the UK Prime Minister's announcement on 23 March 2020 that UK citizens should only leave their homes for certain very limited purposes, we took the decision to...
Angle Plc #AGL announced that University Medical Centre Hamburg-Eppendorf has published results of new work undertaken in non-small cell lung cancer (NSCLC) to investigate the causes of brain metastasis utilising ANGLE's Parsortix system. This ground-breaking research has demonstrated that ALCAM (activated leukocyte cell adhesion molecule) has a key role in causing brain metastasis.
RNS Number: 7696 E Angle PLC 03 March 2020. BREAKTHROUGH RESEARCH HIGHLIGHTS POTENTIAL FOR PARSORTIX TO ASSESS RISK OF BRAIN METASTASIS IN LUNG CANCER. Potential for early detection of patients at risk of brain metastasis in multiple cancers.
Angle Plc #AGL announced that the Istituto Nazionale Tumori di Milano, Milano, Italy has published results of work, which assessed the performance of Parsortix in renal cell carcinoma (RCC) demonstrating key advantages of the Parsortix system.
RNS Number: 2737 E Angle PLC 27 February 2020. ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that Istituto Nazionale Tumori di Milano, Milano, Italy has published results of work, which assessed the performance of Parsortix ® in renal cell carcinoma demonstrating key advantages of the Parsortix system.. Istituto Nazionale Tumori di...
Angle Plc #AGL announced that they will present results of their recent collaboration to develop an integrated workflow for identifying clinical biomarkers on circulating tumor cells (CTCs) at the Molecular Med Tri-Con 2020 Conference in San Francisco (Tri-Con) on March 4, 2020.
ANGLE Plc
AGL.L
ANGLE Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    172.75M

Company Profile

ANGLE is a world leading liquid biopsy company with sample to answer solutions.

Classification

Market Indices-
Watchlist